India's largest private hospital chain, also running pharmacies and a digital-health platform.
India's largest private hospital chain, also running pharmacies and a digital-health platform.
Hospitals earn most of the profit through bed occupancy, fees per patient and the mix of complex procedures. Pharmacy retail and the digital arm bring in a large share of sales but at much lower margins. Apollo was founded in 1983 as India's first corporate hospital chain.
In one line: India's HCA Healthcare plus a CVS-style pharmacy arm.
Moat: narrow (brand, scale, installed base). Strongest brand and largest bed/pharmacy network in Indian private healthcare builds patient and doctor trust.
Headquarters: Chennai, India · Founded: 1983 · Employees: 44,008
Size Apollo Hospitals Enterprise (APOLLOHOSP.NS) is an India Health Care company (Hospital/Nursing Management) with a market value of $13.6B, the 79th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹8,821 on 18 Nov 2026.
Performance Over six months the shares gained 9.9%, against +15.8% for the median peer and +3.8% for the India market (cap-weighted) — 6th lowest of 14 in its peer set.
Growth Revenue grew 19.2% over the last twelve months (peer median +13.1%); the operating margin is 12.1% (peer median 13.4%).
Valuation It trades at 51.0× forward earnings against a peer median of 41.3× (6th most expensive of 15).
Price implies For today's price to make sense, revenue must grow about 33% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.6 points above its cost of capital (11.7% WACC).
Next results Next results expected around 5 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹277B | ₹252B | ₹218B | ₹191B | ₹166B |
| Revenue growth | — | +16% | +14% | +15% | — |
| Gross profit | ₹93.1B | ₹47.7B | ₹40.2B | ₹34.9B | ₹29.9B |
| EBITDA | ₹42.6B | ₹38.1B | ₹30.6B | ₹24.1B | ₹20.8B |
| Net income | ₹22.4B | ₹19.4B | ₹14.5B | ₹8.99B | ₹8.19B |
| Free cash flow | n/a | ₹7.12B | ₹2.16B | ₹5.20B | ₹461M |
| Capital expenditure | n/a | ₹19.6B | ₹17.1B | ₹11.4B | ₹11.3B |
| Total debt | ₹81.5B | ₹84.9B | ₹78.6B | ₹53.3B | ₹43.3B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Apollo Hospitals Enterprise APOLLOHOSP.NS | $13.6B | +10% | +19% | 12% | 51.0× | 33.3% |
| Max Healthcare Institute MAXHEALTH.NS | $10.6B | -4% | +15% | 21% | 55.2× | 45.3% |
| Manipal Health Enterprises MANIPALHOS.NS | $9.69B | n/a | +25% | 19% | 66.5× | 32.9% |
| Fortis Healthcare FORTIS.NS | $6.40B | -17% | +18% | 17% | 48.5× | 42.5% |
| Narayana Hrudayalaya NH.NS | $4.13B | 0% | +71% | 13% | 34.2× | 31.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | APOLLOHOSP.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +14.6% | +9.0% | 5th highest of 15 |
| 6-month return | +9.9% | +15.8% | 6th lowest of 14 |
| Distance from 52-week high | -2.8% | -10.2% | 3rd highest of 15 |
| Revenue growth (TTM) | +19.2% | +13.1% | 6th highest of 15 |
| Operating margin | 12.1% | 13.4% | 6th lowest of 15 |
| Forward P/E | 51.0× | 41.3× | 6th most expensive of 15 |
| Growth the price implies (Req g, 7 yrs) | 33.3% | 14.8% | 4th most demanding of 13 |
| Growth delivered (Del g) | +19.0% | +10.3% | 5th highest of 13 |
| Hurdle (Req g minus delivered) | +14.3 pp | +4.9 pp | 5th most demanding of 13 |
| ROIC minus cost of capital | +2.6 pp | -1.6 pp | 4th highest of 15 |
| EV / EBITDA | 31.2× | 21.6× | 6th most expensive of 15 |
| Net debt / EBITDA | 1.4× | 2.2× | 6th least indebted of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Apollo Hospitals Enterprise APOLLOHOSP.NS | India | $13.6B | +10% | +19% | 12% | 51.0× | 33.3% | +19.0% |
| Universal Health Services UHS | United States | $10.7B | +13% | +8% | 11% | 8.3× | -1.8% | +8.5% |
| Max Healthcare Institute MAXHEALTH.NS | India | $10.6B | -4% | +15% | 21% | 55.2× | 45.3% | +27.2% |
| Manipal Health Enterprises MANIPALHOS.NS | India | $9.69B | n/a | +25% | 19% | 66.5× | 32.9% | +28.8% |
| Tenet Healthcare THC | United States | $21.6B | +45% | +6% | 17% | 13.4× | -1.4% | +3.9% |
| Ramsay Health Care RHC.AX | Australia | $8.31B | +41% | +4% | 5% | 31.4× | 14.0% | +8.3% |
| PACS PACS | United States | $7.35B | +25% | +11% | 8% | 17.5× | 7.5% | +29.7% |
| Chemed CHE | United States | $7.12B | +24% | +5% | 14% | 20.2× | 3.3% | +4.0% |
| Aster DM Quality Care ASTERDM.NS | India | $6.83B | -2% | +50% | 16% | 63.5× | 48.6% | -11.6% |
| Fortis Healthcare FORTIS.NS | India | $6.40B | -17% | +18% | 17% | 48.5× | 42.5% | +17.9% |
| Fresenius SE & Co. KGaA FRE.DE | Germany | $32.7B | +41% | +7% | 10% | 14.7× | 7.0% | -8.8% |
| Narayana Hrudayalaya NH.NS | India | $4.13B | 0% | +71% | 13% | 34.2× | 31.2% | +25.0% |
| Global Health MEDANTA.NS | India | $4.13B | +16% | +26% | 17% | 50.4× | n/a | n/a |
| Surgery Partners SGRY | United States | $3.53B | +100% | +2% | 13% | 77.2× | 15.6% | +12.2% |
| Krishna Institute of Medical Sciences KIMS.NS | India | $3.41B | +2% | +35% | 11% | 81.9× | n/a | n/a |